CD274 and melanoma: Theoretically, PD-1/PD-L1 PET imaging appears to be a bright prospect for monitoring tumor response to immunotherapy and CAR T-cell therapy, and with multiple larger-scale clinical trials underway, including in advanced melanoma, evidence may emerge to support it as a first-line imaging study.